Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xynomic Files Three China INDs for Lead Oncology Candidate

publication date: Dec 27, 2018

Xynomic, a clinical stage Delaware-Shanghai pharma, has filed three China INDs for its lead candidate, abexinostat, a novel HDAC inhibitor. The potentially pivotal trials will test abexinostat, a China Category 1 drug, against renal cell carcinoma and lymphoma. Abexinostat is already in a global Phase III trial, paired with pazopanib, as a first- or second-line therapy for metastatic renal cell carcinoma. Xynonic is an in-licensing company that is developing drugs for China and the US. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here